Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enasidenib after allogeneic stem cell transplantation for IDH2-mutated myeloid malignancies
2019-001416-30Phase 2Completed
- Sponsor
- Heinrich Heine University Düsseldorf
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enasidenib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by Heinrich Heine University Düsseldorf. Primary endpoint: Safety and feasibility of enasidenib as 12-month consolidation after allo-SCT. Started Mar 2020; status: completed.
02
Drugs
enasidenib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on 2019-001416-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001416-30.